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Abstract
The diagnosis and management of obscure gastrointes-
tinal bleeding (OGIB) have changed dramatically since 
the introduction of video capsule endoscopy (VCE) fol-
lowed by deep enteroscopy and other imaging technolo-
gies in the last decade. Significant advances have been 
made, yet there remains room for improvement in our 
diagnostic yield and treatment capabilities for recurrent 
OGIB. In this review, we will summarize the latest tech-
nologies for the diagnosis of OGIB, limitations of VCE, 
technological enhancement in VCE, and different man-
agement options for OGIB. 
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Since the advent of capsule endoscopy, signifi-
cant advances have been made in the imaging of the 
small bowel that allow for the diagnosis and manage-
ment of obscure gastrointestinal bleeding. With a de-
cade of knowledge, it is now appropriate for us to look 
back, critically evaluate our achievements, improve on 
our current technologies and develop ideas to circum-
vent some of the shortcomings. 
Baptista V, Marya N, Singh A, Rupawala A, Gondal B, Cave 
D. Continuing challenges in the diagnosis and management of 
obscure gastrointestinal bleeding. World J Gastrointest Patho-
physiol 2014; 5(4): 523-533  Available from: URL: http://www.
wjgnet.com/2150-5330/full/v5/i4/523.htm  DOI: http://dx.doi.
org/10.4291/wjgp.v5.i4.523
INTRODUCTION
Remarkable progress has been made since 2001 in the de-
velopment of  technologies that are available to investigate 
disorders of  the small intestine. The wireless video cap-
sule endoscope (VCE) and double balloon enteroscope 
became available in 2001, followed by the development of  
computed tomography enterography (CTE) and magnetic 
resonance enterography (MRE). These tools and newer 
variations have allowed us to diagnose and manage small 
bowel lesions in ways that were previously unimaginable. 
After a 10 year period of  remarkable progress it is appro-
priate to look back, critically evaluate where we are, and 
use that evaluation as a springboard to critique the tech-
nologies and circumvent some of  their shortcomings. 
Many studies have shown that the diagnostic yield of  
VCE and deep enteroscopy are similar for obscure gas-
trointestinal bleeding (OGIB) - approximately in the 40% 
to 60% range. The higher numbers are for overt obscure 
bleeding (40% to 92%), occult bleeding (40% to 60%), 
and iron deficiency (10% to 30%). Assuming indications 
for these studies are appropriate, a failure-to-diagnose 
rate of  50% with current techniques appears to be an in-
convenient truth. Similarly, recurrent bleeding is distress-
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ingly common. A recent large study from South Korea 
involving 13 centers and 305 patients showed a detection 
rate of  51.5%. After VCE only 11.8% received interven-
tional treatment. The overall re-bleeding rate was 19% 
during the mean of  30 mo[1]. Interestingly the re-bleeding 
rate was not different between those with positive capsule 
results and those that had therapy. These observations 
confirm that we still have a long way to go in terms of  
better diagnosis and therapy.
DIAGNOSIS OF OGIB
Technology
Various invasive and non-invasive modalities are available for 
the evaluation of  OGIB. These include VCE, deep enteros-
copy and a variety of  radiological modalities such as CTE, 
MRE, and conventional and provocative angiography.
Video capsule endoscopy: Currently there are three 
FDA video capsule endoscopes available in the United 
States (Table 1). PillCam SB2 (now SB3; Given Imaging, 
Yoqneam, Israel), EndoCapsule (now EC-10; Olympus, 
Tokyo, Japan), and MiroCam (IntroMedic, Seoul, South 
Korea). These capsules are all approximately the same 
size (11 × 24-26 mm). Most are able to image for up to 
12 h, thus reducing the occurrence of  incomplete transit. 
The field of  view for all is also similar (140°-156°). 
CapsoCam (Capsovision, Saratoga CA, United 
States) which is in clinical trials in the United States has 
four cameras allowing for 360° imaging. Unlike tradi-
tional capsules that take pictures at a rate of  2-3 frames 
per second (fps), each of  the CapsoCam camera images 
at the rate of  5 fps for the first two hours and thereaf-
ter at 3 fps resulting in 20 and 12 fps respectively. In a 
prospective comparative study by Pioche et al[2], both 
CapsoCam and PillCam SB2 were found to have similar 
diagnostic yield (81.8% and 84.8% respectively), how-
ever, CapsoCam detected significantly more lesions (108 
lesions vs 85 lesions), but had a longer reading time (32.0 
min vs 26.2 min)[2].
MiroCam uses Human Body Communication 
(HBC) for data transmission which is different from 
the radiofrequency telemetry of  PillCam SB2, SB3 and 
EndoCapsule. HBC technology uses the human body 
as a conductive medium for data transmission which ex-
pends less electrical power, thereby conferring a longer 
operating time (12 h) and providing a higher resolution 
of  images (320 × 320 pixels) compared to PillCam SB2 
(256 × 256 pixels)[3]. Complete small bowel examination 
was achieved in 93.3% for MiroCam compared with 
84.3% for PillCam SB2. When comparing both capsules 
for the evaluation of  OGIB, the overall concordance 
was 78.65%, with 77.42% positive agreement and 
79.31% negative agreement. MiroCam also has a 42% 
reduction in missed lesions compared with PillCam[4]. 
However, the longer recording time along with more 
image frames captured per second also translate to lon-
ger reading time, which may negate the 9% higher rate 
of  small bowel completion and lower missed lesion rate 
with MiroCam. 
Overall, the diagnostic yield of  VCE is reported as 
38%-92%[5-7]. With the use of  VCE in the evaluation and 
management of  OGIB, rebleeding rate was noted to be 
15.6% within a 12 mo follow-up period[8]. VCE has the 
highest yield (92.3%) in those with active overt gastrointes-
tinal (GI) bleeding, and the lowest diagnostic yield (12.9%) 
in those with a history of  obscure GI bleeding[9,10]. 
Deep enteroscopy: Deep enteroscopy can be performed 
using double balloon enteroscopy (DBE), single balloon 
enteroscopy (SBE) or through spiral enteroscopy (SE). 
These techniques work by pleating the small bowel back 
over the overtube to minimize looping, thereby allowing 
the enteroscope to advance forward. 
DBE involves two balloons, one each on the distal 
end of  the enteroscope and the overtube. Studies have 
found the diagnostic yield of  DBE is approximately 
60%-80% for evaluating OGIB. Success rate of  total en-
teroscopy, with the evaluation of  the entire small bowel, 
either in the antegrade or antegrade plus retrograde fash-
ion, was reported to be 16%-86%[11]. 
Kamalaporn et al[12] looked at detection rates of  com-
bined DBE following VCE in OGIB. Overall detection 
rates for both techniques were similar. Each technique 
detected lesions not seen by the other, and are comple-
mentary in the evaluation of  OGIB. VCE is generally 
performed before DBE, as it can potentially localize the 
bleeding source and guide the direction of  subsequent 
deep enteroscopy, either in the antegrade or retrograde 
fashion[13]. In a recent systematic review of  over 12000 
DBE over a 10 year period, the most common indica-
tion for performing DBE (62.5%) was for management 
of  suspected bleeding in the small bowel. DBE was suc-
cessful in detecting small bowel bleeding in 68.1%[14]. 
In contrast, SBE involves one balloon. With the use 
of  an angulated enteroscopic tip that can hook onto the 
small bowel, this technique allows for the enteroscope to 
advance with a single balloon. Diagnostic yield and inter-
vention rate of  SBE were similar to that of  DBE (57% vs 
53% and 32% vs 26% respectively)[15], and the procedure 
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Table 1  Specifications of available capsules
MiroCam 
(IntroMedic)
PillCam SB/SB2/
SB3
 (Given Imaging)
EndoCapsule, 
EC-10
(Olympus)
Size (mm) 11 × 24 11 × 26 11 × 26
Weight (g) 3.4 3.45 -
Resolution 
(pixels)
320 × 320 256 × 256 -
Frames per 
second (fps)
3 2 2
Battery life (h) 11 8-12 8-12
Field of view (˚) 150 140/156 145
Communication Human body 
communication
Radiofrequency Radiofrequency
Real time viewer Yes Yes Yes
times were both the same at 60 min[16].
SE consists of  the Endo-Ease Discovery SB which is 
a 118 cm long spiral-shaped overtube with spiral ribbing 
on its surface that is used for enteroscopy via the oral 
route. Diagnostic yield of  SE was 57.1%, similar to that 
of  SBE and DBE, and 60% of  the angioectasias seen 
on VCE were detected during SE[17]. Recurrent overt 
bleeding after SE was 26% during a mean follow up of  
2 years[18]. Compared with DBE, SE had both a shorter 
examination time, along with shorter time to reach the 
farthest point of  examination (43 min vs 65 min and 24 
min vs 43 min respectively). However, DBE allowed for 
deeper advancement of  the enteroscope than SE (310 
min vs 250 cm)[19]. 
A recent comparison review noted similar diagnostic 
yields for SBE, DBE, and SE (53.9%, 64.4%, and 47.0% 
respectively). Procedure time was fastest in the SE group 
(oral: 41.0 min, anal: 46 min) followed by SBE (oral: 
59.8 min, anal: 68.8 min), and DBE (oral: 71.6 min, anal: 
84.5 min). Therapeutic interventions were highest for 
DBE (40.1%), compared with SBE and SE (26.8% and 
29.7%)[20]. 
CTE and MRE: Similar to VCE, CTE may be used in 
the evaluation of  OGIB to provide a potential road map 
prior to performing the more invasive DBE. In compar-
ing CTE and VCE, the diagnostic yield for all findings 
was 34% and 53% respectively. This yield was similar for 
the detection of  neoplastic or mass lesions. However, 
VCE was superior over CTE in the detection of  vascular 
or inflammatory mucosal lesions. In comparing CTE 
with DBE, the diagnostic yield was higher for DBE (78% 
vs 38%). Other studies comparing CTE with digital sub-
traction angiography showed similar yield of  64% and 
60% respectively[21].
Agrawal et al[22] recently reported that in patients 
which VCE failed to localize bleeding, CTE may have a 
utility for the subsequent work up of  overt, but not oc-
cult or OGIB. The authors found the diagnostic yield to 
be 50% in overt GI bleed, but 0% in OGIB. 
MRE may be considered as an alternative for the 
initial examination in patients with clinical suspicion of  
small-bowel stenosis[23] and is also used as a complemen-
tary modality for evaluation of  patients with small bowel 
tumors and Crohn’s disease. 
Angiography: Limited data exists on provocative an-
giography. In a single center series of  patients with 
obscure and recurrent lower GI bleed, Kim et al[24] re-
ported successful definitive treatment of  recurrent hem-
orrhage in 11 of  36 studies (31%) that were performed 
on 34 patients, with only one complication of  ischemic 
bowel perforation that necessitated bowel resection. 
There were otherwise no bleeding complications. Leung 
et al[25] compared VCE and angiography for acute overt 
OGIB and found that the diagnostic yield of  VCE was 
significantly higher than that of  angiography (53.3% vs 
20.0%).
LIMITATIONS OF CAPSULE ENDOSCOPY
Why do we miss lesions? 
It has been reported that VCE missed about 11% of  all 
abnormalities in the small bowel. With single mass le-
sions, the miss rate can be up to 18.9%[26]. Multiple fac-
tors account for missed lesions in VCE, including rapid 
transit through the duodenum and proximal jejunum, 
unidirectional field of  view (about 150°), coupled with 
a non-axial transit which does not permit the camera to 
capture the entirety of  the mucosal surface. This latter 
issue explains the discordance of  repeat capsule studies 
in the same patient. Furthermore, inadequate luminal 
distension and the presence of  luminal contents and bub-
bles further impair complete visualization of  the mucosa. 
Despite the ability of  deep enteroscopes to distend 
the intestine and wash the mucosa, the diagnostic yield 
is comparable to that of  VCE in most patients when the 
first deep enteroscopy is attempted from only one direc-
tion[12]; achievement of  pan enteroscopy is uncommon. 
The field of  view for deep enteroscopes is comparable to 
VCE, thus it may be difficult to see lesions on the distal 
aspect of  a fold. Anesthesia may also alter hemodynam-
ics of  intestinal blood flow in a manner quite different 
to that of  video capsule, and active bleeding originating 
from a submucosal source is not commonly seen.
Preparation for capsule endoscopy 
Capsule image quality plays an important role in the accu-
racy of  capsule interpretation. Presence of  food residue, 
bile, and air bubbles can obscure images. There are cur-
rently no guidelines regarding bowel preparation before 
VCE. Different centers and studies have used various 
regimens including overnight fasting only for 12 h, clear 
liquid diet of  varying duration, and use of  polyethylene 
glycol (PEG) and/or simethicone. Studies evaluating the 
role of  purgatives/prokinetics as bowel preparation for 
VCE have been heterogeneous. In a meta-analysis by 
Song et al[27] and the Korean Gut Image Study Group, 
small bowel visualization quality was found to be en-
hanced fourfold with use of  bowel prep with PEG solu-
tion. Two liter (2 L) of  PEG solution was similarly effec-
tive as 4 L. Diagnostic yield was also slightly improved 
using PEG solution as compared with overnight fast or 
clear liquid diet. In another meta-analysis of  eight ran-
domized controlled trials comparing use of  laxative bow-
el preparation with fasting alone, PEG based regimens 
were found to offer better visibility than fasting alone[28]. 
This is similar to the European Society of  gastrointestinal 
Endoscopy guideline in 2009 recommending purgative 
bowel preparations that would enhance diagnostic yield 
of  VCE[29]. Use of  simethicone with or without bowel 
prep may also enhance image quality. 
Capsule completion rate, however, was not affected 
with the use of  bowel prep, simethicone, or prokinetics. 
Currently overnight fasting is the standard preparation 
for VCE in many centers. Alternatively the ASGE rec-
ommends 2 L of  PEG the evening before the procedure. 
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came from a study by Postgate et al[35] who reported five 
tumors missed on VCE for evaluation of  OGIB. Three 
of  these tumors were in the distal duodenum, one in the 
proximal jejunum, and the fifth was a large Peutz-Jegher’s 
polyp in the proximal ileum. 
In a study by Selby et al[36], capsule endoscopes with 
varying field of  view were evaluated for the ability to 
identify the ampulla of  Vater. The ampulla of  Vater was 
seen in 18% of  PillCam SB2 that has a wider field of  
view (156°) compared to 0% of  PillCam (140°). The Pill-
Cam SB3 has a variable frame rate of  6 fps when moving 
fast. It remains to be seen how effective this enhance-
ment will be in visualizing the ampulla of  Vater and al-
lowing for better identification of  proximal small bowel 
lesions in the future. 
Timing of VCE
The diagnostic yield of  VCE for the evaluation of  
OGIB has been demonstrated to be higher if  VCE is 
performed soon after the onset of  bleeding. Of  one 
hundred consecutive patients evaluated for obscure GI 
bleeding, Pennazio et al[9] reported 92.3% positive yield 
in patients with ongoing overt bleeding (n = 26), 12.9% 
yield in patients with previous overt bleeding (n = 31) 
and 44.2% in patients with guaiac positive stools and 
iron deficiency anemia (n = 43). Similarly, Bresci et al[37] 
reported a positive yield of  91% in patients who under-
went VCE within 15 d of  obscure GI bleed event versus 
a yield of  34% in patients who underwent VCE place-
ment after 15 d. Goenka et al[38] reported that out of  385 
patients investigated for obscure GI bleed, patients with 
VCE placement within 48 h of  overt GI bleed had the 
highest diagnostic yield (87%). This was significantly 
greater (P < 0.05) compared to patients who had VCE 
placed after 48 h (68%) of  overt GI bleed, as well as 
those with occult obscure GI bleed (59%).
Recently our group reported that early use of  VCE 
(i.e., within 3 d of  hospital admission) led to improved 
diagnostic yield, higher rate of  therapeutic interventions, 
along with decreased hospital length of  stay[39]. In the 
early deployment group, VCE findings of  active bleed-
ing or vascular angioectasia were significantly higher than 
in the group where VCE was deployed late (after more 
than 3 d of  admission), or in the group where VCE was 
performed as an outpatient (44.4% vs 27.8% vs 25.8%). 
Therapeutic intervention was also carried out more often 
in the early deployment group compared to the other 
groups (18.9% vs 7.4% for the late group vs 10.3% for 
the outpatient group). Hospital length of  stay was also 
shorter at 6.1 d in the early deployment group, compared 
with 10.3 d in the late deployment group.
Second look video capsule endoscopy
Several studies have shown that VCE can detect a bleed-
ing site in 45%-66% patients with OGIB, and it is often 
felt that patients with OGIB and a negative VCE had a 
low rate of  re-bleeding. However, in a study looking at 
the outcome of  35 patients who had negative VCE for 
Surrounding the controversy regarding use of  bowel 
prep is also the subjective nature of  assessing the cleanli-
ness grading system. Current grading systems such as 
the 10-point quantitative index, or overall assessment of  
adequacy (adequate or inadequate) are either too cum-
bersome to calculate or too simplified to be of  much 
utility. With the goal of  having an objective assessment, 
Van Weyenberg et al[30] designed a scoring system to as-
sess the quality of  bowel preparation with a computed 
quantitative scale using the color intensities of  the tissue 
color bar. This scoring system, known by the authors as 
Computed Assessment of  Cleansing score is an objective 
measure, eliminating subjective interpretation by indi-
vidual readers, and is potentially more reproducible and 
objective. 
Reader error
Recently, a portrayal of  physician performance and er-
ror in capsule reading was shown in a study by Zheng et 
al[31] to play a big role in missed lesions. In this study, 24 
prepared clips of  capsule images were read at different 
modes (single view, duo view, or quad view) and frame 
speed (15, 20, or 25) by 17 endoscopists, ranging from 
novice to experienced readers. The detection rates in this 
study were disappointingly low, ranging from 16% for the 
detection of  blood to 69% for the detection of  angioec-
tasias. As expected, ulcers or erosions were more readily 
detected if  they were larger, and masses or polyps were 
more distinguishable if  their color and texture differ from 
the surrounding mucosa. Abnormal findings appearing 
in more frames were more likely to be picked up than 
those appearing in only 1-2 frames. The overall detec-
tion rate was also significantly higher when reading in the 
single view-15 and quad view-20 modes (45% and 47% 
respectively) compared with reading in single view-25 
(26%). This may be explained by the longer dwell time on 
the screen for each image in quad compared with single 
view. In another study looking at inter-observer agree-
ment in describing VCE findings, the best agreement was 
observed in identifying the presence of  active bleeding, 
whereas the worst agreement was in describing size of  
lesion. Diagnostic concordance was better with angioec-
tasias than for polyps or ulcers/erosions[32]. 
Missed lesions in the proximal small intestine
Several case reports have noted missed lesions on VCE 
that were subsequently detected on other imaging mo-
dalities such as DBE, CTE or MRE. These lesions were 
mostly in the proximal small bowel which can be poorly 
visualized on VCE. This has been evidenced by an ear-
lier study demonstrating that the ampulla of  Vater being 
missed in > 50% of  capsule examinations[33]. In a study 
by Baichi et al[34], VCE was performed on 300 consecutive 
patients presenting with OGIB. Among those patients, 10 
small bowel masses were identified, and of  those lesions 
noted, three duodenal masses were missed on previous 
EGD, with one missed on VCE as well. Further evidence 
of  VCE missing lesions in the proximal small intestine 
Baptista V et al . Obscure GI Bleeding
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the evaluation of  OGIB, the overall re-bleeding rate was 
23% (8 patients) at a median of  15.9 mo of  follow up. 
Four of  these patients underwent repeat endoscopy after 
negative VCE and found previously missed lesions with 
potential as a bleeding source in the stomach. Overall 13 
patients (37%) with or without re-bleeding underwent 
repeat endoscopy after a negative VCE, which lead to 
a definitive diagnosis in nine patients (69% who under-
went repeat endoscopy). Lesions were located in the 
stomach and colon in eight of  these nine patients[40]. In 
another study, Vlachogiannakos et al[41] noted that in 317 
VCE performed for the evaluation of  OGIB with nega-
tive prior upper endoscopy and colonoscopy, a bleeding 
source was found on VCE to be outside the small bowel 
in 3.5% cases, typically duodenum or cecum that was 
missed by conventional upper endoscopy or colonosco-
py. Min et al[42] found a higher diagnostic yield for back-
to-back VCE and showed that for a single VCE, yield 
was 37.5%, which increased to 43.8% with a second 
VCE, and up to 62.5% with back-to-back VCE. There-
fore repeat VCE and/or endoscopic evaluations are 
recommended in cases of  severe anemia, or persistent 
obscure/overt GIB. Timing of  VCE is also important as 
discussed above.
TECHNOLOGICAL ENHANCEMENTS IN 
CAPSULE ENDOSCOPY
Technological enhancements
Abnormal findings may only be present in a few image 
frames, and the usefulness of  VCE relies on accurate 
detection of  these fleeting images. Several features have 
been built-in to capsule endoscopy software with the goal 
of  improving detection, such as Suspected Blood Indica-
tor (SBI) and flexible spectral imaging color enhancement 
(FICE). Different software programs are also equipped 
with special viewing modes to decrease reading time, 
such as with QuickView (Given Imaging) and “auto-
speed-adjusted” and “express-selected” playback modes 
(Olympus).
Suspected blood indicator: SBI automatically high-
lights frames containing several red pixels in an attempt 
to help capsule reader localize bleeding source. However, 
use of  the SBI is identifying clinically significant lesions is 
limited by its low sensitivity 56.4% and specificity 33.5%. 
SBI only has a 24.0% positive predictive value and 67.3% 
negative predictive value[43]. Intra-luminal bubbles created 
many of  the false positive results. Anecdotally, SBI does 
have value in overt bleeding where it becomes a solid red 
bar, the proximal end of  which nearly always marks the 
site of  bleeding.
Flexible spectral imaging color enhancement: FICE 
is an image enhancement system that can obtain bright 
and high-contrast images. In a study looking at the abil-
ity of  FICE to detect angioectasia as compared with 
conventional images, the sensitivity and specificity of  
detecting angioectasia with FICE images were 91% and 
86%, compared with 80% and 100% with conventional 
mode[44]. FICE reading resulted in more false positive le-
sions, which can be correctly identified by converting the 
images to conventional mode. 
Quickview system: The QuickView system scans each 
frame and analyzes patterns/colors to select significant 
images to create a short video that can then be a quick 
preview of  the entire capsule. Even though QuickView 
mode may reduce reading time, prospective trials showed 
a high 8%-12% miss rate[45-47], and it is not recommended 
as a substitute to reading the entire capsule study. 
Auto-speed-adjusted and express-selected playback 
modes: Olympus capsule endoscopy software systems 
have equipped an “auto-speed-adjusted” and “express-
selected”playback modes. There is also an overview 
feature which is a one page summary of  selected still 
images which provides the reader with a quick glance 
of  characteristic frames from the capsule study. In the 
“auto-speed-adjusted” mode, the software speeds up 
the fps of  the video to a maximum of  25 fps when the 
software detects repeated images similar to the previous 
frames, thereby potentially reducing the reading time. In 
the “express-selected” viewing mode, the software skips 
similar images, and produces a running video stream of  
only dissimilar images for viewing by the reader. Those 
skipped images are then gathered into the “expressed-
skipped” mode for subsequent viewing if  necessary. In 
a retrospective study of  70 patients to evaluate the clini-
cal efficacy of  these functions, Subramanian et al[48] not-
ed that the capsule reading time using “express-selected” 
mode with the overview feature was much lower (19 ± 
5 min) than using “auto-speed-adjusted” mode with the 
overview feature (34 ± 10 min). The missed rate was 
8% when the overview function was used alone, but de-
creased to 0.03% when the overview function was com-
bined with either “express-selected” or “auto-speed-
adjusted” playback functions. Though this appears to 
be promising, further prospective evaluation in a large 
multicenter trial is needed before this could be recom-
mended for widespread use in clinical practice. 
Localization
The clinical problem: While video capsule endoscopy 
(VCE) is the gold standard for diagnosis of  small bowel 
bleeding, endoscopists are still faced with the clinical 
challenge of  localizing bleeding sources identified by 
VCE[49,50]. There are many issues at play here. First, the 
small intestine is a featureless tube which offers only two 
reliable landmarks for endoscopists - the pylorus and the 
cecum. Second, the small bowel is stacked upon itself  in 
the peritoneal cavity, meaning that the capsule will tra-
verse through multiple planes as it relates to a single point 
on the abdominal wall. 
Because capsule transit time from the pylorus to the 
cecum is consistently about four hours, current clinical 
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528 November 15, 2014|Volume 5|Issue 4|WJGP|www.wjgnet.com
practice involves identifying time points associated with 
the pylorus and cecum and then noting the time point 
associated with visualization of  the bleeding source. 
Endoscopists can then approximate the distance of  the 
lesion between these two landmarks. One issue with this 
technique is that if  the capsule is not able to visualize the 
cecum (e.g., because of  slow transit time), localization 
solely based on knowing the time point associated with 
the pylorus becomes very inaccurate[51,52]. 
Since the advent of  the video capsule, multiple studies 
have been undertaken to provide a more definitive system 
of  localization. The two major techniques being studied 
are magnetic field and radiofrequency (RF) localization.
Magnetic field localization: Unlike radiofrequencies, 
magnetic fields are unaffected by human tissue, allowing 
for more accurate localization. Magnetic field-based sys-
tems also allow the opportunity to control the movement 
of  the capsule while it travels the small bowel using one 
system[53,54]. Using one system for both capsule control 
and localization, however, will produce interference that 
can obstruct both of  these functions. Given the accuracy 
required to control the movements of  a capsule through 
the bowel, this system may not be appropriate. A second 
issue with magnet-based localization is its application in 
the clinical setting. Specifically, an examination performed 
using this system would require a space containing no 
ferromagnetic materials. Also, magnet-based systems are 
very complex and would be difficult to utilize in clinics[55]. 
Radiofrequency localization: An issue surrounding 
RF-based systems is that radiofrequencies do not easily 
travel through human tissue. In an effort to better un-
derstand the behavior of  radiofrequency signals within 
the human body, a series of  multidisciplinary confer-
ences have been convened to address the problems as-
sociated with what is called body area networking[56,57]. 
What is clear is that RF within the body is influenced by 
multiple factors including tissue densities, juxtaposition 
of  different organs, and other anatomic considerations. 
Despite this, one advantage of  RF-based systems is 
the ease of  utilization in the clinical setting. The first 
commercially available localization system was the RF-
based system attached to the M2A capsule developed by 
Given Imaging[58]. This localization system has been dis-
continued due to its inaccuracy. In addition, this system 
only produces localization data in two dimensions and, 
therefore, its clinical utility is decreased since capsules 
travel in multiple planes. Marya et al[59] recently reported 
on a new RF-based localization system developed by 
Olympus Medical Systems for the new EC-10 capsule. 
This system has similar accuracy to the Given system 
while providing three-dimensional localization instead 
of  only two dimensions. The clinical utility of  this sys-
tem cannot be properly assessed until a prospective trial 
is performed.
Future considerations: Although progress is being 
made in the development of  new localization systems, 
there are still issues to be addressed. Research needs to be 
focused on developing a localization system that provides 
information related to the distance the capsule travels 
from the pylorus to the suspected bleeding lesion. It is 
this distance, not simply the three-dimensional location 
of  a capsule within the abdominal cavity, which has the 
greatest clinical utility to an endoscopist or surgeon in the 
management of  obscure GI bleeding.
MANAGEMENT OF OGIB
Therapeutic options
While progress is being made in the diagnosis of  lesions 
contributing to obscure GI bleeding, the clinical chal-
lenge of  treating the suspected lesions persists. Tradition-
ally, analysis of  particular therapeutic options has been 
limited to case series or small clinical trials. The decision 
to choose a particular option is based on several factors. 
Specifically, clinicians consider where the suspected le-
sions are within the GI tract, the number of  suspected 
lesions at risk of  further bleeding, the degree of  bleeding 
and anemia, co-morbidities and the severity of  symptoms 
experienced by the patient before deciding on a particular 
therapeutic intervention.  
Endoscopic therapy
Once an obscure lesion is localized through endoscopy, 
the endoscopist has several options available for treat-
ment. Treatments include APC and endoscopic band 
ligation (EBL).
Argon plasma coagulation: APC therapy is the gold 
standard therapy for gastric antral vascular ectasias 
(GAVE) and is widely used to treat angioectasia through-
out the GI tract[60-62]. A prospective study by Kwan et 
al[63] provided definitive evidence of  the usefulness of  
APC therapy in 100 patients with both angioectasia and 
GAVE. In their study the authors found that in a previ-
ously transfusion-dependent subset of  subjects, over 
half  did not require further transfusions post-APC. In a 
smaller study population, Herrera et al[64] demonstrated a 
90% success rate for APC therapy in patients with focal 
vascular ectasias. In that study, APC was not associated 
with any adverse effects. Other studies have reported a 
2.5% rate of  adverse events[65]. 
Endoscopic band ligation: Historically, EBL has been 
a treatment for esophageal varices, but its usefulness as 
a treatment for GAVE and other angioectasia through-
out the GI tract is now being realized[66]. In a study of  
22 patients, Wells et al[67] demonstrated the benefits of  
EBL, as a subgroup receiving the therapy required fewer 
treatment sessions and had better-controlled bleeding 
than those receiving thermal therapy. Earlier studies have 
shown an equal efficacy and safety profile for EBL in the 
treatment of  Dieulafoy’s lesions compared to hemostatic 
clips or injection therapy[68]. 
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Future directions: Despite important advances in treat-
ments, a large prospective study comparing endoscopic 
therapies is lacking. As diagnostic measures improve, such 
a study could prove vital in allowing endoscopists more 
opportunities to treat obscure GI bleeds.  
Pharmacologic therapy 
If  multiple lesions are suspected to be throughout the 
GI tract, or if  a patient is found to have persistent 
bleeding despite repeated endoscopic or surgical inter-
ventions, pharmacologic therapy should be considered. 
Pharmacologic therapy may also be pursued for patients 
with multiple medical co-morbidities that may make 
them poor candidates for repeated endoscopy or surgical 
interventions.
Hormonal therapy: The utilization of  hormonal ther-
apy (i.e., estrogen plus progesterone) for the treatment 
of  suspected vascular malformations in the GI tract 
originated from the treatment of  hereditary hemorrhagic 
telangiectasia (HHT, also known as Rendu-Osler-Weber 
disease). Much of  the support for this therapy, however, 
came only from case reports or from studies with very 
small sample sizes.
van Cutsem et al[69] demonstrated a significant benefit 
of  hormonal therapy compared to placebo (failure rate 
of  therapy 29% compared to 100% for placebo). Despite 
impressive results, there are many significant issues with 
this study. Specifically, the sample size of  patients was 
small and the study population included several individu-
als with HHT who represent a small sub-population of  
patients with OGIB[69]. These results have been countered 
by other studies including a larger more recent study 
from Junquera et al[70], which demonstrated no definitive 
benefit from hormonal therapy compared to the placebo. 
As other studies suggest, the pathogenesis of  vascular 
malformations in the GI tract is quite different from the 
process associated with HHT[71,72]. Currently, there is no 
definitive evidence for the efficacy of  hormonal therapy 
in GI bleeding that is unrelated to HHT.
Anti-angiogenics: The pathogenesis of  vascular malfor-
mations related to GI bleeding provides multiple options 
for therapy. In particular, much focus has been placed on 
the role of  vascular endothelial growth factors (VEGF) in 
the development of  these lesions. Junquera et al[73] dem-
onstrated that patients with recurrent bleeding secondary 
to intestinal angiodysplasias (AD) have accumulations of  
VEGF along the endothelial lining of  colonic resection 
specimens. Research suggests that VEGF becomes over-
expressed in oxygen-depleted mucosa, contributing to 
the formation of  AD in older tissues[74,75]. This role of  
VEGF in the development of  AD has created a niche for 
anti-angiogenic therapy in AD-associated bleeding.  
Thalidomide (which has been used in Crohn’s disease 
patients due to its anti-TNF effects) is now being studied 
in patients with AD-related bleeding. Recently, Ge et al[76] 
performed a randomized controlled trial demonstrat-
ing the efficacy of  thalidomide in treating AD, 71.4% 
of  patients responded, compared to 3.7% in the control 
group. Although these results are promising there are 
significant adverse events associated with thalidomide 
therapy including leukopenia, deep vein thrombosis, 
and peripheral neuropathy[77]. Bevacizumab is another 
anti-angiogenic medication recently studied as a VEGF-
inhibitor. Studies have demonstrated its usefulness as an 
antiangiogenic medication for colon and renal cancer, 
but there have been no formal studies performed in pa-
tients with recurrent GI bleeding from suspected vascu-
lar malformations[78].  
Somatostatin analogues: The most well-studied soma-
tostatin analogue for the treatment of  OGIB is octreo-
tide. The suspected mechanism of  action is the ability to 
inhibit the production of  intestinal enzymes (e.g., chole-
cystokinin, gastrin, and vasointestinal peptide), decrease 
splanchnic blood flow, decrease platelet aggregation, and 
decrease angiogenesis. One case series by Nardone et al[79], 
demonstrated that octreotide treatment stopped bleed-
ing in 10 of  17 patients. The authors noted that patients 
receiving octreotide therapy experienced few side effects. 
The most common side effects of  octreotide therapy 
are abdominal discomfort and diarrhea, considered to be 
relatively mild compared to side effects of  some of  the 
other therapies listed here[80].
Future directions: While the pathogenesis of  AD-
related bleeding offers multiple promising opportunities 
for intervention, a focus on developing randomized-
controlled trials to better assess these therapies is needed 
to define their clinical utility and potential side effects.
Surgical therapy
With advances in endoscopic techniques that allow for 
visualization and treatment of  lesions responsible for 
OGIB, surgery has become less of  a necessity. Now, sur-
gery may be pursued in patients who have failed medical 
and endoscopic therapy, as well as patients who present 
with an acute hemorrhage. But in all cases a target le-
sion needs to be defined preoperatively to avoid the high 
likelihood of  a negative exploration. Research in this field 
has focused on the localization of  lesions to allow sur-
geons the opportunity to make a curative resection. Stud-
ies have demonstrated the benefits of  injecting methylene 
blue dye as an intraoperative technique to allow surgeons 
to identify the areas of  the bowel affected by AD[81,82]. 
Although this technique has been used since 1978, recent 
studies have suggested adaptations to make the process 
easier. For example, D’Mello et al[83] presented a case 
report using digital subtraction angiography to reveal a 
vascular malformation which they then accessed easily 
using a microcatheter. Further investigation into capsule 
endoscopy localization and intraoperative localization of  
lesions will allow surgeons to make more definitive resec-
tions while decreasing the length of  bowel needed to be 
removed.
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RECURRENCE OF OGIB
One of  the biggest challenges associated with OGIB 
is that of  recurrence. The rate of  re-bleeding varies in 
literature depending on center, duration of  follow up 
and cause of  bleeding. Studies have demonstrated the 
re-bleeding rate to be in the range of  40%-60% when 
associated with a finding of  angiodysplasia on VCE[84,85]. 
Endo et al[86] studied the rate of  re-bleeding after inter-
vention for lesions detected on VCE, and found 50% 
re-bleeding rate in patients with angiodysplasia despite 
endoscopic intervention. The re-bleeding rate was also 
higher for patients with clinically insignificant lesions, 
regardless of  whether endoscopic intervention was per-
formed[86]. Patients requiring multiple transfusions for 
recurrent bleeding typically have multiple co-morbidities, 
such as chronic renal failure or use of  anticoagulation, 
that are also independent risks for re-bleeding. Patients 
with recurrent bleeding require multiple endoscopic pro-
cedures and are thus at increased risk of  complications 
from these procedures.
Another challenge associated with recurrent OGIB 
is negative endoscopic findings on VCE or deep enter-
oscopy. Evidence is conflicting in this area with some 
studies showing a higher rate of  bleeding with normal 
mucosa or insignificant lesions on endoscopy[84], whereas 
others show higher rate of  recurrent bleeding associated 
with positive findings on VCE[85]. Studies have reported 
re-bleeding rate as low as 5.6% and 11% in patients with 
negative VCE[85,87]. Koh et al[88] investigated long-term 
outcome in OGIB after negative VCE, and found that 
the overall re-bleeding rate was 28.4%. The re-bleeding 
rate was higher in patients with positive VCE (36.8%) 
than in those with negative findings (22.8%)[88]. It is also 
reported that in VCE-directed interventions, 50%-66% 
of  patients remain transfusion-free without recurrent 
bleeding[89,90]. 
FUTURE IN THE DIAGNOSIS AND 
MANAGEMENT OF OGIB
Advances in capsule endoscopy have included longer bat-
tery life, higher image capture frame rate, wider angle of  
view, improved image resolution, along with enhanced 
software features to assist in reading. Studies suggest that 
there is room for further education in reading VCE vid-
eos. The more widespread use of  early capsule deploy-
ment in overt OGIB should enhance diagnostic yields 
and increase therapeutic intervention rates. The ability 
to define distance travelled by the capsule would be very 
helpful in lesion localization. The new 3-D localization 
software is a step in the right direction. Difficult to detect 
sources of  bleeding may be better controlled by medical 
means and should stimulate drug development and clini-
cal trials of  such agents. The tools for deep enteroscopy 
are likely to evolve shortly. However, cost constraints for 
these procedures would preclude their primary deploy-
ment in most parts of  the world. Thus VCE and DE are 
likely to remain complimentary procedures for the fore-
seeable future.
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